Patents by Inventor Fernand Narbey Torossian

Fernand Narbey Torossian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6806253
    Abstract: A therapeutical vaccine complex having activity specific for Helicobacter bacteria as well as non-specific immunomodulation activity for regulating the natural defenses of the body. The drug is also useful for preventing relapses, particularly in cases of resistance to conventional treatment. The drug essentially consists of RNA, selective membrane fractions of microbial germs, particular amino acid sequences, sodium chloride and a steroidal anti-inflammatory in predetermined proportions enabling simultaneous delivery of antibiotics and frenosecretories. Said drug is particularly suitable for treating digestive tract diseases caused by Helicobacter (antral gastritis, duodenal ulcers, gastric ulcers, oesophagitis, hepatitis) and preventing stomach cancer and degenerative infectious MALT (mucosa-associated lymphoid tissue) lymphoma, as well as coronary diseases directly or indirectly dependent on Helicobacter infections.
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: October 19, 2004
    Inventor: Fernand Narbey Torossian
  • Patent number: 6503512
    Abstract: An immunomodulator complex for inhibiting intracellular replication of HIV retrovirus comprises cellular membrane fractions from at least one bacterial microorganism, and ribosomal RNA of that microorganism. The ribosomal RNA is covalently coupled to a glycoprotein amino acid sequence of type III collagen.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: January 7, 2003
    Inventor: Fernand Narbey Torossian
  • Publication number: 20020032152
    Abstract: A therapeutical vaccine complex having activity specific for Helicobacter bacteria as well as non-specific immunomodulation activity for regulating the natural defences of the body, is disclosed. The drug is also useful for preventing relapses, particularly in cases of resistance to conventional treatment. The drug essentially consists of RNA, selective membrane fractions of microbial germs, particular amino acid sequences, sodium chloride and a steroidal anti-inflammatory in predetermined proportions enabling simultaneous delivery of antibiotics and frenosecretories. Said drug is particularly suitable for treating digestive tract diseases caused by Helicobacter (antral gastritis, duodenal ulcers, gastric ulcers, oesophagitis, hepatitis) and preventing stomach cancer and degenerative infectious MALT (mucosa-associated lymphoid tissue) lymphoma, as well as coronary diseases directly or indirectly dependent on Helicobacter infections.
    Type: Application
    Filed: August 25, 1998
    Publication date: March 14, 2002
    Inventor: FERNAND NARBEY TOROSSIAN